2019-11-15T06:24:33-06:00 2018-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2018-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY % LINDA JENSEN CFO CONQ 5714831700 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2019-11-11 true Marc Berger P01871563 7038930600 4.35.255.34 54621820193195000009 2019-11-15 P C44969C09172B32DC5279494C6AE8494327A5917 F80C4C4CE64063363A32333BB37C43EAD2BBFD59 2018 2020-03-31 21:24:44Z CLIFFORD HUDIS MD 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 64833532 false X www.conquer.org X 1999 VA CONQUERING CANCER WORLDWIDE BY FUNDING BREAKTHROUGH RESEARCH AND SHARING CUTTING-EDGE KNOWLEDGE. CONQUER CANCER'S VISION IS A WORLD FREE FROM THE FEAR OF CANCER. 16 15 0 161 0 29032906 31933505 0 0 908055 1229060 86135 4425 30027096 33166990 16371345 15819973 0 0 0 0 0 121000 2412288 8534237 7943766 24905582 23884739 5121514 9282251 69434052 74547914 4262501 4353781 65171551 70194133 X CONQUER CANCER (), THE ASCO FOUNDATION, FUNDS RESEARCH INTO EVERY FACET OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. IN 1964, SEVEN ONCOLOGISTS CREATED THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), NOW A GLOBAL NETWORK OF NEARLY 45,000 CANCER PROFESSIONALS. AS ASCO'S FOUNDATION, CONQUER CANCER HELPS TURN SCIENCE INTO A SIGH OF RELIEF FOR PATIENTS AROUNDS THE WORLD BY SUPPORTING GROUNDBREAKING RESEARCH AND EDUCATION ACROSS CANCER'S FULL CONTINUUM. false false 7748381 6540871 PROFESSIONAL EDUCATION - CONQUER CANCER HELPS ONCOLOGY PROFESSIONALS WORLDWIDE STAY UP TO DATE ON THE LATEST DEVELOPMENTS AND DISCOVERIES IN CANCER KNOWLEDGE. CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S COMPREHENSIVE SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH LIVE MEETINGS AND PRINT AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2018 INCLUDE THE FOLLOWING: * THE ASCO ANNUAL MEETING FEATURED NEARLY 265 EDUCATIONAL AND SCIENTIFIC SESSIONS. MORE THAN 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY AND ATTRACTS MORE THAN 40,000 ATTENDEES WORLDWIDE. THE MEETING OFFERS HEALTHCARE PROFESSIONALS PROVIDING ONCOLOGY CARE AN IMPORTANT OPPORTUNITY TO COME TOGETHER TO EXPLORE THE LATEST ADVANCES IN SCIENCE; CONTEXTUALIZE RECENT DISCOVERIES AND OPTIMIZE TREATMENT AND RESEARCH STRATEGIES; FRAME AND DISCUSS MAJOR CONTROVERSIES IN THE FIELD; AND NETWORK WITH PEERS IN AN ENVIRONMENT CHARGED WITH THE EXCITEMENT OF A COMMON GOAL: PROGRESS TOWARD BETTER OUTCOMES FOR PATIENTS. * GASTROINTESTINAL CANCERS (GI) SYMPOSIUM - THE ANNUAL GI SYMPOSIUM IS THE PREMIERE MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY A COMMITTEE WITH REPRESENTATIVES FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE (AGA INSTITUTE), THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF SURGICAL ONCOLOGY (SSO), WITH ADDITIONAL CONTENT ADVISORS FROM THE SOCIETY OF THORACIC SURGEONS (STS) AND THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD). * GENITOURINARY CANCERS (GU) SYMPOSIUM - THE ANNUAL GU SYMPOSIUM IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY COMMITTEES WITH REPRESENTATIVES FROM THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO), AND THE SOCIETY OF UROLOGIC ONCOLOGY (SUO). * BEST OF ASCO - WITH THE FIELD OF CANCER CARE CONSTANTLY EVOLVING AND EXPANDING, THE BEST OF ASCO MEETINGS BRING TOGETHER EXPERT FACULTY TO SYNTHESIZE THE MOST IMPORTANT RESEARCH AND CLINICAL DEVELOPMENTS PRESENTED AT THE ASCO ANNUAL MEETING AND TO DISCUSS PRACTICAL APPLICATIONS FOR PATIENT CARE. A PANEL OF ASCO EXPERTS SELECTS ABSTRACTS THAT HIGHLIGHT THE IMPORTANT SCIENTIFIC INFORMATION TO CREATE THE BEST OF ASCO MEETING PROGRAM. THIS PROGRAM PROVIDES ACCESS TO THE MOST CUTTING-EDGE, PRACTICE-CHANGING RESEARCH PRESENTED AT THE MEETING IN A RESPONSIBLE, PEER-REVIEWED MANNER. * PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM - THE PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM PROVIDES INFORMATION THAT IS VITAL TO THE ENTIRE CANCER CARE CONTINUUM, FROM LABORATORY RESEARCH REGARDING BIOLOGIC MECHANISMS OF SYMPTOMS TO CARING FOR PATIENTS PSYCHOSOCIAL AND SPIRITUAL NEEDS DURING CANCER TREATMENT AND AT END OF LIFE. THE SYMPOSIUM INCLUDES CONTENT IN BOTH PALLIATIVE CARE, WHICH IS PROVIDED THROUGHOUT THE TRAJECTORY OF DISEASE, AS WELL AS SUPPORTIVE CARE. THE SYMPOSIUM FOCUSES ON THE SCIENTIFIC BASIS OF SYMPTOMS AND THEIR TREATMENT, MODELS OF INTEGRATED CARE DELIVERY AND QUALITY OF LIFE AND IS COSPONSORED BY FOUR LEADING MEDICAL SPECIALTY SOCIETIES: THE AMERICAN ACADEMY OF HOSPICE AND PALLIATIVE MEDICINE (AAHPM), THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER (MASCC). *QUALITY CARE SYMPOSIUM - THE ASCO QUALITY CARE SYMPOSIUM PROVIDES A FORUM TO SHARE THE LATEST STRATEGIES AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCE, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, AND QUALITY AND SAFETY IN THE CANCER CARE FIELD. THE SYMPOSIUM BRINGS TOGETHER LEADERS IN THE FIELD TO SHARE STRATEGIES AND METHODS FOR MEASURING AND IMPROVING THE QUALITY OF CANCER CARE AND DISSEMINATES INFORMATION ON THE IMPROVEMENT OF THE QUALITY OF PATIENT AND SURVIVOR CARE THROUGH IMPLEMENTATION SCIENCE AND METHODS FOR QUANTIFICATION OF PATIENT EXPERIENCES, PROVIDER EFFICIENCY, CLINICAL OUTCOMES, SAFETY, AND VALUE. *IMMUNO-ONCOLOGY SYMPOSIUM - THE ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM EXPLORES CLINICAL AND TRANSLATIONAL RESEARCH IN IMMUNO-ONCOLOGY AND IMPLICATIONS FOR PATIENT CARE. THE SYMPOSIUM FACILITATES IMPORTANT EDUCATIONAL AND SCIENTIFIC DIALOGUES ON CLINICAL DEVELOPMENTS ACROSS DISEASE SITES IN THE RAPIDLY ADVANCING FIELD OF IMMUNO-ONCOLOGY, AND HELPS MEET THE WIDESPREAD NEED FOR EDUCATION IN RESPONSE TO A PARADIGM SHIFT IN CANCER TREATMENT THAT TARGETS THE IMMUNE SYSTEM RATHER THAN THE TUMOR. THE SYMPOSIUM IS DEVELOPED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) AND THE SOCIETY FOR THE IMMUNOTHERAPY OF CANCER (SITC). *CANCER SURVIVORSHIP SYMPOSIUM - THIS UNIQUE SYMPOSIUM UNITES A VARIETY OF SPECIALISTS AND DISCIPLINES TO ADDRESS ALL ASPECTS OF SURVIVORSHIP CARE INCLUDING COMMUNICATION, HEALTH PROMOTION, CARE COORDINATION, LONG-TERM EFFECTS MANAGEMENT, PSYCHOSOCIAL ISSUES, AND RECURRENCE AND SECOND MALIGNANCIES. THE MEETING OFFERS A DISTINCT OPPORTUNITY FOR CLINICIANS TO KEEP PACE WITH RAPIDLY EVOLVING BEST PRACTICES AND GUIDELINES FOR ONGOING CARE OF PATIENTS WHO HAVE RECEIVED A CANCER DIAGNOSIS. THE SYMPOSIUM IS DEVELOPED BY A COMMITTEE WITH REPRESENTATIVES FROM THE AMERICAN COLLEGE OF PHYSICIANS (ACP), THE AMERICAN ACADEMIC OF FAMILY PHYSICIANS (AAFP), AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). HIGHLIGHTS OF PRINT AND ELECTRONIC PROFESSIONAL EDUCATION MATERIALS SUPPORTED BY CONQUER CANCER AND AVAILABLE TO THE PUBLIC IN 2018 INCLUDE THE FOLLOWING: *MEETING LIBRARY- ASCOS MEETING LIBRARY IS A ONE-STOP LOCATION TO ACCESS ABSTRACTS, EDUCATIONAL BOOK MANUSCRIPTS, VIDEOS, SLIDES, AND POSTERS PRESENTED AT ASCOS MEETINGS. ASCOS MEETING LIBRARY IS AN INTEGRAL INFORMATIONAL AND EDUCATIONAL RESOURCE FOR ASCO MEMBERS, OTHER PHYSICIANS, PEOPLE WITH CANCER, AND THE GENERAL PUBLIC. THE 2018 ASCO MEETING LIBRARY INCLUDES THE FOLLOWING: ABSTRACTS: ASCOS COMPREHENSIVE ONLINE DATABASE OF ONCOLOGY-RELATED RESEARCH ABSTRACTS FROM THE PREVIOUS 5 YEARS. THIS INCLUDES LINKS TO RELATED PRESENTATIONS AND ADDITIONAL ABSTRACTS. VIDEOS AND SLIDES (FORMERLY VIRTUAL MEETING): ASCO VIDEOS AND SLIDES USE THE LATEST TECHNOLOGY TO DELIVER NEARLY 45,000 ORAL PRESENTATIONS AND ORAL ABSTRACTS FROM ASCO MEETINGS AND SYMPOSIA DATING BACK TO 2010. THE MOST COMPREHENSIVE COLLECTION OF ONCOLOGY-RELATED MEDIA IS AVAILABLE ONLINE FOR PHYSICIANS, RESEARCHERS, AND PATIENTS. MEETING POSTERS: POSTERS FROM GENERAL POSTER AND POSTER DISCUSSION SESSIONS FOR ASCO ANNUAL MEETING, GASTROINTESTINAL CANCERS SYMPOSIUM, GENITOURINARY CANCERS SYMPOSIUM, ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM, CANCER SURVIVORSHIP SYMPOSIUM, ASCO QUALITY CARE SYMPOSIUM, AND THE PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM, AS FAR BACK AS 2010. ARCHIVED CONTENT IS AVAILABLE FOR MEETINGS NO LONGER OFFERED, INCLUDING MARKERS IN CANCER AND THE BREAST CANCER SYMPOSIUM. *ASCO CLINICAL GUIDELINES MOBILE APPLICATION - ASCO DEVELOPS AND PUBLISHES CLINICAL PRACTICE GUIDELINES TO SERVE AS A GUIDE FOR DOCTORS AND OUTLINE APPROPRIATE METHODS OF TREATMENT AND CARE. THE GUIDELINES CAN ALSO ADDRESS SPECIFIC DISEASE-ORIENTED CLINICAL SITUATIONS, AS WELL AS USE OF APPROVED MEDICAL PRODUCTS, PROCEDURES, AND TESTS. THE ASCO CLINICAL PRACTICE GUIDELINES MOBILE APPLICATION IS DESIGNED TO MAKE ASCO GUIDELINES MORE USER-FRIENDLY BY PROVIDING ACCESS AT THE BEDSIDE AND/OR IN CLINIC BY MEMBERS OF THE ONCOLOGY CARE TEAM, WITH THE ULTIMATE RESULT OF IMPROVING PATIENT CARE BASED ON ESTABLISHED SCIENCE AND THE LATEST RESEARCH. THE MOBILE APPLICATION IS AVAILABLE FOR THE APPLE IOS AND ANDROID OPERATING SYSTEMS, ACCESSIBLE BY SMARTPHONES AND TABLETS. INTERACTIVE TOOLS ARE ALSO INCLUDED WITHIN SOME GUIDELINES. 7879590 6567818 RESEARCH - THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER HAS A DEMONSTRATED TRACK RECORD IN SUPPORTING THE EARLY CAREER DEVELOPMENT OF ONCOLOGY RESEARCHERS, INCLUDING IDENTIFYING AND NURTURING THOSE WHO HAVE BECOME NOTABLE LEADERS AND INNOVATORS IN THE FIELD. PAST GRANT RECIPIENTS HAVE BECOME HEADS OF LARGE CANCER INSTITUTIONS AND PRESIDENTS OF MAJOR ONCOLOGY SOCIETIES, AS WELL AS GUIDED THE NATIONAL ONCOLOGY CONVERSATION THROUGH SERVICE ON BOARDS AND COMMITTEES. ADDITIONALLY, PAST RECIPIENTS HAVE ALSO INVESTED IN THE NEXT GENERATION OF YOUNG INVESTIGATORS BY SERVING AS MENTORS TO NEWLY CHOSEN CONQUER CANCER GRANTEES. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. EACH YEAR, CONQUER CANCER FUNDS AND AWARDS MULTIPLE RESEARCH GRANTS DESIGNED TO HELP ATTRACT AND RETAIN THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TO SUPPORT THEIR EFFORTS. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $126 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,100 RECIPIENTS IN 75 COUNTRIES. HIGHLIGHTS OF 2018 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: ADVANCED CLINICAL RESEARCH AWARD (ACRA) - $450,000 PROVIDED ONE (1) THREE-YEAR AWARD TO SUPPORT A PHYSICIAN-SCIENTIST COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH IN BREAST CANCER. THIS RESEARCH MUST HAVE A PATIENT-ORIENTED FOCUS, INCLUDING A CLINICAL RESEARCH STUDY AND/OR TRANSLATIONAL RESEARCH INVOLVING HUMAN SUBJECTS CAREER DEVELOPMENT AWARD (CDA) - $3,000,000 PROVIDED FIFTEEN (15) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. YOUNG INVESTIGATOR AWARD (YIA) - $3,600,000 PROVIDED SEVENTY-TWO (72) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD - $309,602 PROVIDED SIX (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS CONDUCTING RESEARCH IN LOW RESOURCE SETTINGS ON SCIENTIFIC QUESTIONS SPECIFIC TO THOSE SETTINGS, WITH THE POTENTIAL TO OFFER "REVERSE INNOVATION" INSIGHTS TO INFLUENCE ONCOLOGY PRACTICE IN A WIDE RANGE OF RESOURCE SETTINGS, BY INVESTIGATORS IN HIGH RESOURCE SETTINGS ON ISSUES IN RESOURCE-LIMITED SETTINGS, OR COLLABORATIVE RESEARCH BETWEEN INVESTIGATORS IN BOTH HIGH AND LOW RESOURCE SETTINGS ON QUESTIONS OF SHARED CONCERN. THE GOAL FOR THE GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD IS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY, AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. THE JAMES B. NACHMAN JUNIOR FACULTY AWARD IN PEDIATRIC ONCOLOGY WAS ESTABLISHED IN MEMORY OF JAMES B. NACHMAN, MD, AN INTERNATIONALLY RENOWNED PEDIATRIC CANCER EXPERT AND PEDIATRICS PROFESSOR. HE CHAIRED SEVERAL CHILDREN'S ONCOLOGY GROUP NATIONAL STUDY COMMITTEES AND WAS AN AUTHORITY IN THE MEDICAL MANAGEMENT OF CHILDHOOD CANCERS, ESPECIALLY LEUKEMIA AND LYMPHOMA. $3,000 PROVIDED FOR ONE JUNIOR FACULTY MEMBER WITH THE HIGHEST-SCORING ABSTRACT IN PEDIATRIC ONCOLOGY. MERIT AWARDS- $211,000 PROVIDED FOR TWO-HUNDRED AND TEN (210) MERIT AWARDS WHICH PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AND INTERACT WITH OTHER CLINICAL CANCER INVESTIGATORS AT ASCO SCIENTIFIC MEETINGS AND DISEASE-SPECIFIC SYMPOSIA. 3329770 2350000 QUALITY AND ACCESS TO CARE - REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH-QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED. THE QUALITY AND ACCESS TO CARE PROGRAMS AND INITIATIVES SUPPORTED BY CONQUER CANCER IN 2018 INCLUDE THE FOLLOWING: DIVERSITY IN ONCOLOGY INITIATIVE - THE CONQUER CANCER GRANTS AND AWARDS PROGRAM PROVIDES FUNDING FOR DIFFERENT TYPES OF AWARD OPPORTUNITIES FOR ONCOLOGY FELLOWS, CLINICAL PRACTICES, AND INTERNATIONAL RESEARCHERS. ONE OF THE PROGRAMS OFFERED THROUGH CONQUER CANCER IS THE DIVERSITY IN ONCOLOGY INITIATIVE. THE DIVERSITY IN ONCOLOGY INITIATIVE WAS STRUCTURED TO FACILITATE THE RECRUITMENT AND RETENTION OF INDIVIDUALS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE TO CANCER CAREERS, WITH PARTICULAR ATTENTION TO THE DEVELOPMENT OF CLINICAL PRACTITIONERS AND INVESTIGATORS. THE DIVERSITY IN ONCOLOGY PROGRAM CONSISTS OF AWARD OPPORTUNITIES FOR MEDICAL STUDENTS AND RESIDENTS WHO SELF-IDENTIFY AS UNDERREPRESENTED MINORITIES (URMS). TWO AWARD OPPORTUNITIES ARE AVAILABLE: THE MEDICAL STUDENT ROTATION PROVIDES CLINICAL OR CLINICAL RESEARCH ONCOLOGY ROTATIONS FOR US MEDICAL STUDENTS FROM URM BACKGROUNDS AND THE RESIDENT TRAVEL AWARD PROVIDES FINANCIAL SUPPORT FOR URM RESIDENTS TO ATTEND THE ASCO ANNUAL MEETING *QUALITY TRAINING PROGRAM - AS THE LEADING ONCOLOGY QUALITY IMPROVEMENT (QI) COURSE, ASCOS QUALITY TRAINING PROGRAM EMPOWERS PRACTICE TEAMS TO IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE BY TEACHING TEAMS HOW TO BALANCE QUALITY IMPROVEMENT PROJECTS WITH DEMANDING SCHEDULES AND COMPETING PRIORITIES. CONTENT HAS BEEN DEVELOPED SPECIFICALLY FOR ONCOLOGY PRACTICE TEAMS. THE ASCO QUALITY TRAINING PROGRAM INCLUDES ACCESS TO RENOWNED FACULTY AND COACHES DURING FIVE FOCUSED DAYS OF IN-PERSON LEARNING. DURING THOSE FIVE DAYS, PRACTICE TEAMS ATTEND THREE SESSIONS, WHICH INCLUDE SEMINARS, CASE EXAMPLES, AND SMALL GROUP EXERCISES. LEARNING CONTINUES THROUGHOUT THE SIX-MONTH COURSE, INCLUDING REMOTE COACHING SESSIONS AS NEEDED. EACH TEAM WILL TAKE ITS QUALITY IMPROVEMENT KNOWLEDGE AND SKILLS TO ANOTHER LEVEL, ACCELERATING CHANGE AND IMPROVEMENT. TEAMS WILL WORK ON A PROBLEM OF THEIR OWN CHOOSING, WHICH COULD RANGE FROM IMPROVING CARE COORDINATION OR PATIENT SAFETY TO A SPECIFIC ORAL CHEMOTHERAPY PROJECT. 1166025 186284 PATIENT EDUCATION & INFORMATION 1264696 175000 INTERNATIONAL PROGRAMS 2430721 361284 21388462 true true false false false false false false false true false false false false false true true true false false true true true true true false false true true true false false false false false false false false true true false false false true false false false true 141 0 true 0 true false false false false false true true false false false false false false X 16 15 true false true false false true true true true false false true true true true true true false false false AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X LINDA JENSEN CFO 5714831320 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 Thomas Roberts Jr MD Chair 1.0 0.0 X X 0 0 0 Sandra Swain MD FACP Treasurer 1.0 0.0 X X 0 0 0 Claire A Huang Secretary 1.0 0.0 X X 0 0 0 Clifford Hudis MD FACP CEO 7.5 30.0 X X 0 864309 24173 Alexander W Casdin Board Member 1.0 0.0 X 0 0 0 Howard A Burris III MD Board Member 1.0 0.0 X 0 0 0 Thomas Marsland MD FASCO Board Member 1.0 0.0 X 0 0 0 Lawrence H Einhorn MD FASCO Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD FASCO Board Member 1.0 0.0 X 0 0 0 Raj Mantena RPh Board Member 1.0 0.0 X 0 0 0 Robert Mayer MD FASCO Board Member 1.0 0.0 X 0 0 0 Margaret Tempero MD FASCO Board Member 1.0 0.0 X 0 0 0 Steven Rosen MD FACP Board Member 1.0 0.0 X 0 0 0 Aaron Sasson Board Member 1.0 0.0 X 0 0 0 Gerald J McDougall Board Member 1.0 0.0 X 0 0 0 Susan L Cohn MD FASCO Board Member 1.0 0.0 X 0 0 0 Don Welsh Board Member 1.0 0.0 X 0 0 0 Nancy Daly MS MPH EXEC VP & CHIEF PHILAN OFFICER 36.5 1.0 X 0 369808 38168 LINDA JENSEN CPA CFO 7.5 30.0 X 0 414231 38168 ERIN HULTMAN CPA MST CFO (PARTIAL YEAR) 37.5 0.0 X 0 174154 23814 0 1822502 124323 0 false true false TRUE NORTH INC 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 DIGITAL ADVERTISING 935300 THE LUKENS COMPANY 2800 SHIRLINGTON RD 9TH FLOOR ARLINGTON VA 22204 MAILING SERVICES 552873 STRATUSLIVE 6465 COLLEGE PARK SQUARE SUITE 400 VIRGINIA BEACH VA 23464 DONORMGMT IT SERV. 182715 FREEMAN AUDIO VISUAL PO BOX 650519 DALLAS TX 75265 AUDIO VISUAL SERVICE 120710 GSW WORLDWIDE PO BOX 505214 ST LOUIS MO 63150 HEALTHCARE ADVERTISE 103286 6 16663 575000 683235 3050004 27608603 1682396 31933505 0 719934 719934 0 0 0 0 0 32115222 31606096 509126 509126 509126 64871 683235 60446 4425 4425 0 0 0 0 0 0 0 33166990 1233485 14397883 14397883 673784 673784 748306 748306 0 0 0 0 0 0 0 0 0 0 4780554 4063470 47806 669278 60223 5 60218 19097 16232 192 2673 0 121000 121000 26355 26355 452370 153439 1458 297473 166858 129358 1500 36000 190097 152530 863 36704 850605 198139 2331 650135 0 228105 194028 2272 31805 333999 240068 149 93782 0 190218 190209 9 0 0 0 0 POSTAGE 136523 11095 62 125366 BANK & CREDIT CARD FEES 35728 30369 357 5002 BAD DEBT EXPENSE 100000 100000 0 0 PRINTING 325986 88857 634 236495 47048 690 1 46357 23884739 21388462 83989 2412288 5800837 9246912 0 0 9225263 7889011 0 889 0 0 0 0 0 0 0 0 58987 188502 0 0 51505977 56118569 0 0 0 0 0 0 2842988 1104031 69434052 74547914 462741 458665 2925010 2857504 874750 1037612 0 0 0 0 0 0 0 0 0 0 0 0 4262501 4353781 X 36530778 35258849 11981283 17363529 16659490 17571755 65171551 70194133 69434052 74547914 9282251 -4259669 X false true X true false X 36399446 29974390 23158842 29032906 31998377 150563961 0 0 36399446 29974390 23158842 29032906 31998377 150563961 45787752 104776209 929857 833497 877067 908055 719934 4268410 0 0 154832371 0.67671 0.67384 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 17114411 2133374 -964377 711653 17571755 10363214 6170675 1125396 544874 17114411 9169527 1364000 280187 450500 10363214 3968976 5417500 -94449 122500 9169527 4031095 9750 110331 182200 3968976 1.00000 false false 0 0 X 28941412 -4259669 -4259669 33201081 26355 -60446 -34091 33166990 23918830 60446 60446 23858384 26355 26355 23884739 PART V, LINE 4 Permanently restricted net assets of donor-restricted endowment funds are preserved, absent explicit direction from the donor. Interest from the permanently restricted funds is intended to fund future research and/or educational awards. PART V, LINE 1A-1G ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. PART X, LINE 2 IN ACCORDANCE WITH GAAP, THE FOUNDATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE FOUNDATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2015. PART XII, LINE 4b FUNDRAISING EXPENSES $60,446 PART XI, LINE 2d FUNDRAISING EXPENSES $60,446 true East Asia and the Pacific Program Services Awards & Grants 13620 Europe (Including Iceland and Greenland) Program Services Awards & Grants 78360 North America Program Services AWARDS & GRANTS 422400 South America Program Services AWARDS & GRANTS 47486 Sub-Saharan Africa Program Services AWARDS & GRANTS 182205 South Asia Program Services AWARDS & GRANTS 30500 Russia and the Newly Independent States Program Services AWARDS & GRANTS 1260 Central America and the Caribbean Investments 3506370 4282201 4282201 North America Career Development Award 300000 CHECK South America GLOBAL ONCOLOGY YOUNG INVESTIGATOR 45386 CHECK Europe (Including Iceland and Greenland) Young Investigator Award 50000 CHECK Sub-Saharan Africa INT'L INNOVATION GRANT 20000 CHECK Sub-Saharan Africa LONG TERM INT'L FELLOWSHIP 115000 CHECK North America YOUNG INVESTIGATOR 50000 CHECK Sub-Saharan Africa GLOBAL ONCOLOGY YOUNG INVESTIGATOR 39820 CHECK North America GLOBAL ONCOLOGY YOUNG INVESTIGATOR 25100 CHECK North America INT'L INNOVATION 20000 CHECK South Asia INT'L INNOVATION 20000 CHECK 10 IDEA AWARD East Asia and the Pacific 13 13620 CHECK IDEA AWARD Europe (Including Iceland and Greenland) 29 29620 CHECK IDEA AWARD North America 27 27300 CHECK IDEA AWARD South America 2 2100 CHECK IDEA AWARD South Asia 9 10500 CHECK IDEA AWARD Sub-Saharan Africa 6 7385 CHECK false false false false false false PART I, LINE 2: EXPLANATION: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. X X X X X X true THE LUKENS COMPANY GENERAL false 374656 121000 253656 374656 121000 253656 AL CA CO CT DC FL GA KS KY ME MD MA MI MS NV NH NJ NY NC ND OK OR PA RI SC TN UT WA WI RESEARCH DINNER 522285 457415 64870 28267 32179 women who conqu 90907 90907 7 134913 134913 748105 683235 64870 28267 32179 60446 4424 FORM 990, SCHEDULE G, PART I, LINE 1 THE RETAINER FEES ARE PAID FOR THE WORK THAT LUKENS DOES ON MANAGING OUR ACCOUNT. THIS INCLUDES STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. THE OTHER FEES ARE FOR THE PRODUCTION OF THE ACTUAL MAILINGS THEMSELVES, POSTAGE, PRINTING, ACTUAL LIST RENTALS, ETC. true Columbia University Medical Center 630 West 168th Street New York NY 10032 135598093 501(C)(3) 250000 YIA Dana-Farber Cancer Institute 44 Binney Street Boston MA 02115 042263040 501(C)(3) 1450000 CDA, GOYIA, YIA Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(C)(3) 199296 GOYIA, YIA Johns Hopkins University 3400 N CHARLES STREET Baltimore MD 212182608 520595110 501(C)(3) 200000 YIA Massachusetts General Hospital 55 Fruit St Boston MA 021142696 041564655 501(C)(3) 250000 YIA Mayo Clinic Minnesota 200 First St SW Rochester MN 55905 416011702 501(C)(3) 300000 CDA, YIA Memorial Sloan Kettering Cancer Center (MSKCC) 1275 York Avenue New York NY 10065 131624182 501(C)(3) 750000 CDA, YIA Stanford University 800 Welch Road Stanford CA 943055796 941156365 501(C)(3) 117000 MSRA, YIA The Ohio State University 300 W 10th Ave Columbus OH 43210 316025986 501(C)(3) 50000 YIA The University of North Carolina at Chapel Hill 102 Mason Farm Rd Chapel Hill NC 27599 566001393 501(C)(3) 100000 GOYIA, YIA The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard Houston TX 77030 746001118 501(C)(3) 1300000 acraBC, CDA, goyia, YIA University of California Los Angeles 10833 Le Conte Ave Los Angeles CA 90095 956006143 501(C)(3) 200000 CDA University of California San Francisco 2340 Sutter St San Francisco CA 94115 946036493 501(C)(3) 100000 YIA University of Pennsylvania 16th Floor Penn Tower Philadelphia PA 191044283 231352685 501(C)(3) 50000 YIA University of Washington 4333 Brooklyn Ave NE Seattle WA 981959472 916001537 501(C)(3) 50000 YIA Yale University 333 Cedar Street New Haven CT 065208028 060646973 501(C)(3) 200000 CDA PRESIDENT & FELLOWS OF HARVARD COLLEGE 641 HUNTINGTON AVENUE BOSTON MA 02115 042103560 501(C)(3) 200000 CDA WAKE FOREST BAPTIST MEDICAL CENTER 1 MEDICAL CENTER BLVD WINSTON SALEM NC 27157 510190238 501(C)(3) 200000 CDA WASHINGTON UNIVERSITY IN SAINT LOUIS CAMPAS BOX 1054 ONE BROOKINGS DRIVE ST LOUIS MO 631304862 430653611 501(C)(3) 200000 CDA GEORGETOWN UNIVERSITY 37TH O STREET NW WASHINGTON DC 20057 530196003 501(C)(3) 50000 YIA H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DR TAMPA FL 33612 592451713 501(C)(3) 50000 YIA SEATTLE CHILDREN'S HOSPITAL 1100 OLIVE WAY SEATTLE WA 98101 910564748 501(C)(3) 50000 YIA ST JUDE CHILDREN'S RESEARCH HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 50000 YIA UNIVERSITY OF ALABAMA AT BIRMINGHMAN MEDICAL CTR 1720 2ND AVENUE SOUTH BIRMINGHAM AL 35293 636005396 501(C)(3) 50000 YIA UNIVERSITY OF CALIFORNIA SAN DIEGO 3855 HEALTH SCIENCES DRIVE LA JOLLA CA 920930658 956006144 501(C)(3) 50000 YIA UNIVERSITY OF PITTSBURGH 5150 CENTRE AVENUE SUITE 500 PITTSBURGH PA 15232 250965591 501(C)(3) 50000 YIA UNIVERSITY OF ROCHESTER MEDICAL CENTER 601 ELMWOOD AVE BOX 704 ROCHESTER NY 14642 160743209 501(C)(3) 50000 YIA UNIVERSITY OF WISCONSIN 21 N PARK STREET SUITE 6401 MADISON WI 537151218 396006492 501(C)(3) 50000 YIA VANDERBILT UNIVERSITY MEDICAL CENTER 691 PRESTON RESEARCH BUILDING NASHVILLE TN 381053678 352528741 501(C)(3) 50000 YIA WINSHIP CANCER INSTITUTE OF EMORY UNVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 50000 YIA 30 Merit Awards 145 145000 Patient Advocate Scholarships 35 61784 MEDICAL STUDENT ROTATION AWARD 10 37000 RESIDENT TRAVEL AWARD 5 7500 PART I, LINE 2 CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CCF AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CCF'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. part II, award abbreviations: YIA: Young investigator award CDA: Career Development award MSRA: Medical Student Rotation Award ACRABC: Advanced Clinical REsearch award in breast cancer GOYIA: GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD Part II, Column 1: Name and Address of Organization JOHNS HOPKINS UNIVERSITY 3400 N. CHARLES STREET BALTIMORE, MD 21218-2608 WAKE FOREST BAPTIST MEDICAL CENTER 1 MEDICAL CENTER BLVD. WINSTON SALEM, NC 27157 UNIVERSITY OF CALIFORNIA, SAN DIEGO 3855 HEALTH SCIENCES DRIVE LA JOLLA, CA 92093-0658 UNIVERISTY OF ROCHESTER MEDICAL CENTER 601 ELM WOOD AVE NE, BOX 704 ROCHESTER, NY 14642 VANDERBILT UNIVERSITY MEDICAL CENTER 691 PRESTON RESEARCH BLDG NASHVILLE, TN 38105-3678 UNIVERSITY OF PENNSYLVANIA 16TH FLOOR PENN TOWER PHILADELPHIA, PA 19104 WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY 1599 CLIFTON RD NE, 4TH FLOOR ATLANTA, GA 30322 false false false false false false false false false Clifford Hudis MD FACP CEO 0 794784 0 69525 0 0 0 20625 0 3548 0 888482 0 0 Nancy Daly MS MPH EXEC VP & CHIEF PHILAN OFFICER 0 364808 0 5000 0 0 0 20625 0 17543 0 407976 0 0 LINDA JENSEN CPA CFO 0 379231 0 35000 0 0 0 20625 0 17543 0 452399 0 0 ERIN HULTMAN CPA MST CFO (PARTIAL YEAR) 0 166154 0 8000 0 0 0 12461 0 11353 0 197968 0 0 PART I, LINE 3: EXPLANATION: COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 2 1375 FMV X 14 1617526 FMV X VARIOUS SILENT AUCTION ITEMS 72 63495 FMV false true false FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES PATIENT EDUCATION AND INFORMATION - WELL-INFORMED, EDUCATED PATIENTS ARE THEIR OWN BEST ADVOCATES, AS WELL AS INVALUABLE PARTNERS FOR DOCTORS. CONQUER CANCER SUPPORTS PROGRAMS AND ACCURATE, DOCTOR-APPROVED CANCER INFORMATION AND RESOURCES BOTH IN PRINT AND ONLINE, THAT EDUCATE PATIENTS AND THE PUBLIC ABOUT CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. FUNDING IN THIS AREA ALLOWS CONQUER CANCER TO CONTINUE AND EXPAND OUR WORK TO INFORM PATIENTS. HIGHLIGHTS OF PATIENT EDUCATION AND INFORMATION PROGRAMS AND ACTIVITIES SUPPORTED BY CONQUER CANCER IN 2018 INCLUDE THE FOLLOWING: PATIENT ADVOCATE SCHOLARSHIP PROGRAM- THE PATIENT ADVOCATE SCHOLARSHIP PROGRAM PROVIDES THE OPPORTUNITY FOR ADVOCATES TO ATTEND ASCOS SCIENTIFIC MEETINGS TO GAIN THE EDUCATION, KNOWLEDGE, AND SKILLS NECESSARY TO PARTICIPATE IN PATIENT ADVOCACY AND THE CANCER RESEARCH PROCESS. THE SCHOLARSHIPS ALSO ENABLE ADVOCATES TO PROMOTE THEIR ORGANIZATIONS PROGRAMS, SERVICES, AND RESOURCES AND TO NETWORK WITH ONE ANOTHER AS WELL AS WITH ONCOLOGY PROFESSIONALS. IN 2018, $119,604 IN FUNDING ALLOWED 65 PATIENT ADVOCATES TO ATTEND THE ASCO MEETINGS. CANCER.NET- CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. THE WEBSITE PROVIDES TIMELY, COMPREHENSIVE INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS ALL CONTENT IS SUBJECT TO A FORMAL PEER-REVIEW PROCESS BY THE CANCER.NET EDITORIAL BOARD, COMPOSED OF MORE THAN 150 MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS, PHYSICIAN ASSISTANTS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENT ADVOCATES AND INCLUDES PEER-REVIEWED INFORMATION ON MORE THAN 120 TYPES OF CANCER AND SYNDROMES, INCLUDING RISK FACTORS, DIAGNOSIS, FINDING AN ONCOLOGIST, TREATMENT, MANAGING SIDE EFFECTS, CLINICAL TRIALS, AND AFTER TREATMENT, CAREGIVING, COPING STRATEGIES, AND SURVIVORSHIP. INFORMATION IS DELIVERED IN WRITTEN ARTICLES, VIDEOS, AND AUDIO PODCASTS. THIS INFORMATION IS MADE AVAILABLE FREE TO THE PUBLIC. INTERNATIONAL PROGRAMS - ASCO AND THE CONQUER CANCER FOUNDATION SHARE AN INTERNATIONAL MISSION TO ENGAGE THE PHYSICIAN AND THE HEALTHCARE PROFESSIONAL COMMUNITY ON A GLOBAL SCALE TO IMPROVE CARE TO CANCER PATIENTS AND ENHANCE THE EXCHANGE OF KNOWLEDGE TO FACILITATE ADVANCES IN THE CARE OF PEOPLE WITH CANCER EVERYWHERE. CONQUER CANCER FUNDS SUPPORT INTERNATIONAL PROGRAMS INCLUDING EDUCATION, FELLOWSHIP AND GRANT OPPORTUNITIES TO ENABLE ONCOLOGISTS FROM OPPOSITE ENDS OF THE WORLD TO SHARE IDEAS AND BUILD LASTING COLLABORATIONS THAT CAN ENHANCE PATIENT CARE LOCALLY AND GLOBALLY. CONQUER CANCER FUNDS SPECIFICALLY SUPPORTING INTERNATIONAL ACTIVITIES INCLUDE THE FOLLOWING: LONG-TERM INTERNATIONAL FELLOWSHIP (LIFE)- $115,000 PROVIDED ONE (1) LONG-TERM INTERNATIONAL FELLOWSHIP TO AN EARLY-CAREER ONCOLOGIST IN a DEVELOPING NATION TO ADVANCE THEIR TRAINING BY DEEPENING THEIR RELATIONSHIP WITH A UNITED STATES OR CANADIAN COLLEAGUE AND HIS OR HER INSTITUTION. THROUGH A ONE-YEAR FELLOWSHIP THE RECIPIENT WILL EARN VALUABLE TRAINING AND EXPERIENCE WITH WHICH THEY CAN AFFECT CHANGE IN CANCER CARE IN THEIR HOME COUNTRY. RECIPIENTS MUST RETURN TO THEIR HOME INSTITUTIONS AFTER COMPLETING THEIR FELLOWSHIP AND ARE EXPECTED TO DISSEMINATE THE KNOWLEDGE THEY HAVE GAINED. INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)- $30,150 PROVIDED TWENTY-FOUR (24) INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS FOR ONCOLOGISTS IN DEVELOPING COUNTRIES TO PARTICIPATE IN THE ASCO ANNUAL MEETING AND VISIT A CANCER CENTER IN THE UNITED STATES OR CANADA. THIS AWARD WAS DESIGNED TO PROVIDE CONTINUING MEDICAL EDUCATION, ASSIST IN CAREER DEVELOPMENT AND HELP TO ESTABLISH STRONG RELATIONSHIPS WITH LEADING ASCO MEMBERS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. INTERNATIONAL INNOVATION GRANT (IIG) - $60,000 PROVIDED THREE (3) INTERNATIONAL INNOVATION GRANTS TO SUPPORT NOVEL AND INNOVATIVE PROJECTS THAT CAN HAVE A SIGNIFICANT IMPACT ON CANCER CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES (LMCS). THE INTERNATIONAL INNOVATION GRANT PROGRAM IS INTENDED TO SUPPORT PROPOSALS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2018, THE BOARD OF DIRECTORS OF CONQUER CANCER INCLUDED SIXTEEN (16) DIRECTORS WITH VOTING RIGHTS, AND TWO (2) WITHOUT VOTING RIGHTS. ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS HAVE THE SAME VOTING RIGHTS. DURING THE REPORTED TAX YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS CONSISTENT WITH CONQUER CANCER'S BYLAWS. THE EXECUTIVE COMMITTEE IS COMPOSED OF SIX MEMBERS OF THE BOARD OF DIRECTORS, WHO ARE THE CHAIR OF THE BOARD OF DIRECTORS, THE CEO, THE SECRETARY, THE TREASURER, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHOPIC OFFICER (NON-VOTING), AND A SIXTH DIRECTOR WHO IS NOMINATED BY THE CHAIR OF THE BOARD AND ELECTED BY A MAJORITY OF THE VOTING MEMBERS OF THE BOARD OF DIRECTORS. ALL OF THE MEMBERS OF THE EXECUTIVE COMMITTEE EXCEPT THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER ARE ENTITLED TO VOTE. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY CONQUER CANCER'S BYLAWS, WHICH PROVIDE THAT EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW AND EXCEPT AS SPECIFIED IN THE BYLAWS, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH CONQUER CANCER'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING INDIVIDUALS SERVED AS OFFICERS OF, AND WERE EMPLOYED BY, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), A RELATED 501(C)(3) ORGANIZATION: DR. CLIFFORD HUDIS SERVED AS THE CHIEF EXECUTIVE OFFICER; LINDA JENSEN SERVED AS THE CHIEF FINANCIAL OFFICER; AND DINA MICHELS SERVED AS THE SENIOR VICE PRESIDENT, CHIEF LEGAL OFFICER, AND SECRETARY. THEY THEREFORE EACH HAD A BUSINESS RELATIONSHIP WITH THE OTHER TWO OFFICERS. IN ADDITION, THE FOLLOWING INDIVIDUALS WERE EMPLOYED BY ASCO: NANCY DALY AND ERIN HULTMAN. THEY THEREFORE EACH HAD A BUSINESS RELATIONSHIP WITH THE OTHER OFFICERS DESCRIBED IN THE PARAGRAPH ABOVE. FORM 990, PART VI, SECTION A, LINE 4 IN 2018, CONQUER CANCER MADE THE FOLLOWING SIGNIFICANT CHANGE TO ITS BYLAWS: - THE REQUIREMENT THAT AT LEAST A MAJORITY OF THE TOTAL NUMBER OF APPOINTED DIRECTORS MUST BE MEMBERS IN GOOD STANDING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) WAS REMOVED. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE CONQUER CANCER FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS BEFORE IT WAS FILED. THE CONQUER CANCER FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER, THE CEO, AND THE GENERAL COUNSEL PRIOR TO FILING. ALSO THE FINANCE COMMITTEE OF THE BOARD OF DIRECTORS REVIEWED A DRAFT OF THE FORM 990 BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINES 15A & 15B THE FOLLOWING EMPLOYEES OF ASCO SERVE AS OFFICERS OF CONQUER CANCER: CEO OF CONQUER CANCER (ALSO SERVES AS CEO OF ASCO) EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER OF CONQUER CANCER CFO OF CONQUER CANCER GENERAL COUNSEL OF CONQUER CANCER (ALSO SERVES AS VP/GENERAL COUNSEL OF ASCO) INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD 800 ALEXANDRIA VA 22314 136180380 education NY 501(C)(3) 10 NA false false true true true false false false false false false true true false true true true true false false